Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Immatics is a biotechnology business based in the US. Immatics shares (IMTX) are listed on the NASDAQ and all prices are listed in US Dollars. Immatics employs 382 staff and has a trailing 12-month revenue of around $150.9 million.
Finder Award
SoFi Invest
Finder Award
eToro
Robinhood
| Latest market close | $8.34 |
|---|---|
| 52-week range | $5.75 - $13.60 |
| 50-day moving average | $9.25 |
| 200-day moving average | $9.60 |
| Wall St. target price | $19.57 |
| PE ratio | 14.5789 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $0.57 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $8.34 from 2023-02-03
| 1 week (2023-01-31) | 2.84% |
|---|---|
| 1 month (2023-01-06) | -11.65% |
| 3 months (2022-11-07) | -20.11% |
| 6 months (2022-08-05) | -33.01% |
| 1 year (2022-02-07) | -12.85% |
|---|---|
| 2 years (2021-02-05) | -24.52% |
| 3 years (2020-02-03) | N/A |
| 5 years (2018-02-03) | N/A |
Valuing Immatics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Immatics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Immatics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 15x. In other words, Immatics shares trade at around 15x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Immatics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $17.7 million.
The EBITDA is a measure of a Immatics's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $150.9 million |
|---|---|
| Operating margin TTM | 9.18% |
| Gross profit TTM | $-52,811,000 |
| Return on assets TTM | 3.13% |
| Return on equity TTM | 45.83% |
| Profit margin | 22.5% |
| Book value | $1.72 |
| Market capitalisation | $633.4 million |
TTM: trailing 12 months
We're not expecting Immatics to pay a dividend over the next 12 months.
Over the last 12 months, Immatics's shares have ranged in value from as little as $5.75 up to $13.6. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Immatics's is 0.5555. This would suggest that Immatics's shares are less volatile than average (for this exchange).
Immatics N. V. , a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate.
Everything we know about the Neuraxis IPO, plus information on how to buy in.
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.